Lytenava (bevacizumab-vikg)

Nearly 20 million U.S. adults live with some form of age-related macular degeneration (AMD). Wet AMD accounts for approximately 10% of AMD cases but is responsible for 90% of legal blindness attributable to AMD. Global AMD prevalence was estimated at 196 million people in 2020, projected to increase to 288 million by 2040. In a U.S. claims analysis, the estimated annual all-cause cost for a patient with neovascular AMD (nAMD) was $24,520, and global estimates place the cost of visual impairment due to AMD at $343 billion, including $255 billion in direct healthcare costs.